# Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer

> **NCT03199274** · PHASE2 · COMPLETED · sponsor: **Thomas Jefferson University** · enrollment: 104 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Yttrium-90 Microsphere Radioembolization
- **DRUG:** Perflutren Protein-Type A Microspheres
- **PROCEDURE:** Dynamic Contrast-Enhanced Ultrasound Imaging

## Key facts

- **NCT ID:** NCT03199274
- **Lead sponsor:** Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2024-02-27
- **Final completion:** 2025-01-23
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2026-01-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199274, "Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03199274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*